109 related articles for article (PubMed ID: 34564974)
21. Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.
Fernandes LC; Kim SB; Matos D
World J Gastroenterol; 2005 Feb; 11(5):645-8. PubMed ID: 15655814
[TBL] [Abstract][Full Text] [Related]
22. [Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].
Wu F; Chen L; Wu W; Jiang B; Su X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):443-449. PubMed ID: 28440527
[TBL] [Abstract][Full Text] [Related]
23. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
[TBL] [Abstract][Full Text] [Related]
24. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
Zhu FL; Ling AS; Wei Q; Ma J; Lu G
Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640
[TBL] [Abstract][Full Text] [Related]
26. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
[TBL] [Abstract][Full Text] [Related]
27. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
Yang XQ; Li Y; Chen C; Peng CW; Liu SP; Liu Y
Med Oncol; 2011 Sep; 28(3):789-95. PubMed ID: 20373053
[TBL] [Abstract][Full Text] [Related]
28. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Okulczyk B
Dig Dis Sci; 2005 Jun; 50(6):1019-24. PubMed ID: 15986847
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
Huh JW; Lee WY; Park YA; Cho YB; Yun SH; Kim HC; Chun HK
J Cancer Res Clin Oncol; 2014 Mar; 140(3):435-41. PubMed ID: 24414039
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
31. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
32. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes.
Guo G; Wang Y; Zhou Y; Quan Q; Zhang Y; Wang H; Zhang B; Xia L
J Immunother Cancer; 2019 Jul; 7(1):179. PubMed ID: 31300050
[TBL] [Abstract][Full Text] [Related]
33. Models of logistic regression analysis, support vector machine, and back-propagation neural network based on serum tumor markers in colorectal cancer diagnosis.
Zhang B; Liang XL; Gao HY; Ye LS; Wang YG
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323037
[TBL] [Abstract][Full Text] [Related]
34. [Diagnostic value of
Zhang XC; Zhang JH; Wang RF; Fan Y; Fu ZL; Yan P; Zhao GY; Bai YX
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):1071-1077. PubMed ID: 31848507
[TBL] [Abstract][Full Text] [Related]
35. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients.
Zhang H; Chen C; Wang S; Li X; Fan T
J BUON; 2020; 25(1):80-86. PubMed ID: 32277617
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
38. Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer.
Liu F; Du F; Chen X
World J Surg Oncol; 2014 Nov; 12():333. PubMed ID: 25381564
[TBL] [Abstract][Full Text] [Related]
39. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the significance of expression of CEA mRNA and levels of CEA and its related proteins in colorectal cancer patients.
Wang W; Li Y; Zhang X; Jing J; Zhao X; Wang Y; Han C
J Surg Oncol; 2014 Apr; 109(5):440-4. PubMed ID: 24783267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]